Keros Therapeutics, Inc. Annual Income Tax Expense (Benefit) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Keros Therapeutics, Inc. annual/quarterly Income Tax Expense (Benefit) history and growth rate from 2019 to 2023.
  • Keros Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending December 31, 2022 was $0.000, a 100% decline year-over-year.
  • Keros Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending December 31, 2022 was $0.000, a 100% decline year-over-year.
  • Keros Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $0.000.
  • Keros Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $0.000, a 100% decline from 2021.
  • Keros Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was $2.01M.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $0 $0 Jan 1, 2023 Dec 31, 2023 10-K 2024-02-28
2022 $0 -$2.01M -100% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-28
2021 $2.01M +$2.18M Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 -$172K -$172K Jan 1, 2020 Dec 31, 2020 10-K 2022-03-09
2019 $0 Jan 1, 2019 Dec 31, 2019 10-K 2021-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.